PREVALENCE AND TREATMENT OF GENITOURINARY CONDITIONS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS
Author(s)
Gries K1, Cai B2, Yu R3, Kuti E2, Sander S2, Hareendran A4
1Evidera, Seattle, WA, USA, 2Boehringer Ingelheim, Ridgefield, CT, USA, 3Evidera, Bethesda, MD, USA, 4Evidera, Inc., London, UK
OBJECTIVES: To assess the prevalence of and predictors associated with genitourinary (GU) conditions among patients with type 2 diabetes mellitus (T2DM) and to understand the treatment pathways patients employ when these conditions occur. METHODS: An internet-based survey was conducted in July 2014. The sample recruited from YouGov PollingPoint Panel in the U.S. included 2,000 adults with T2DM diagnosed by a physician for at least one year and treated with T2DM medications. Participants who reported a GU condition (urinary tract infection [UTI] and/or genital infection [GI] including genital yeast infection, bacterial vaginosis/vaginitis [BV], or balanitis) in the past 12 months were asked to complete survey questions about their GU conditions. Descriptive analysis and logistic regressions were performed. RESULTS:
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PDB63
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders